CA3249636A1 - Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissues - Google Patents
Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissuesInfo
- Publication number
- CA3249636A1 CA3249636A1 CA3249636A CA3249636A CA3249636A1 CA 3249636 A1 CA3249636 A1 CA 3249636A1 CA 3249636 A CA3249636 A CA 3249636A CA 3249636 A CA3249636 A CA 3249636A CA 3249636 A1 CA3249636 A1 CA 3249636A1
- Authority
- CA
- Canada
- Prior art keywords
- nutraceutical
- pharmaceutically
- solvate
- acceptable salt
- therapeutically
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22382390 | 2022-04-25 | ||
| EP22382390.7 | 2022-04-25 | ||
| PCT/EP2023/060827 WO2023208944A1 (en) | 2022-04-25 | 2023-04-25 | Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3249636A1 true CA3249636A1 (en) | 2023-11-02 |
Family
ID=81579974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3249636A Pending CA3249636A1 (en) | 2022-04-25 | 2023-04-25 | Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissues |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250268855A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4514147A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025515358A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119343061A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3249636A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024013203A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023208944A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190146A1 (ar) * | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| US11246846B2 (en) * | 2017-10-23 | 2022-02-15 | Michael S. Tempesta | Trisodium citrate compositions having enhanced uptake across digestive mucosa |
-
2023
- 2023-04-25 US US18/859,892 patent/US20250268855A1/en active Pending
- 2023-04-25 CA CA3249636A patent/CA3249636A1/en active Pending
- 2023-04-25 WO PCT/EP2023/060827 patent/WO2023208944A1/en not_active Ceased
- 2023-04-25 EP EP23722509.9A patent/EP4514147A1/en active Pending
- 2023-04-25 JP JP2024563636A patent/JP2025515358A/ja active Pending
- 2023-04-25 CN CN202380049301.0A patent/CN119343061A/zh active Pending
-
2024
- 2024-10-25 MX MX2024013203A patent/MX2024013203A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4514147A1 (en) | 2025-03-05 |
| CN119343061A (zh) | 2025-01-21 |
| MX2024013203A (es) | 2025-02-10 |
| JP2025515358A (ja) | 2025-05-14 |
| WO2023208944A1 (en) | 2023-11-02 |
| US20250268855A1 (en) | 2025-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Irisin protects against LPS-stressed cardiac damage through inhibiting inflammation, apoptosis, and pyroptosis | |
| Reggiori et al. | Autophagy: more than a nonselective pathway | |
| Yang et al. | Polysaccharides from Armillariella tabescens mycelia ameliorate renal damage in type 2 diabetic mice | |
| JP5176964B2 (ja) | ジペプチジルペプチダーゼiv阻害剤 | |
| Trinidad-Calderon et al. | Maize bioactive peptides: From structure to human health | |
| JP2020007371A (ja) | 抗肥満及び抗糖尿作用を有するペプチド及びその用途 | |
| US10155022B2 (en) | Fat accumulation inhibitory peptide and pharmaceutical composition for preventing or treating obesity containing the same | |
| Qi et al. | Whey protein peptides PEW and LLW synergistically ameliorate hyperuricemia and modulate gut microbiota in potassium oxonate and hypoxanthine-induced hyperuricemic rats | |
| AU2017356160A1 (en) | Methods of treating liver disease | |
| US12219938B2 (en) | Mouse model of alcohol-induced liver cancer | |
| Liu et al. | Antihypertensive activities of a solid-state culture of Taiwanofungus camphoratus (Chang-Chih) in spontaneously hypertensive rats | |
| CN117919232B (zh) | 吲哚丙酸在治疗肝硬化以及免疫性肝损伤的应用 | |
| Zhang et al. | Conjugated linoleic acid (CLA) reduces intestinal fatty acid uptake and chylomicron formation in HFD-fed mice associated with the inhibition of DHHC7-mediated CD36 palmitoylation and the downstream ERK pathway | |
| You et al. | Ameliorative effect of mussel-derived ACE inhibitory peptides on spontaneous hypertension rats | |
| Ganai et al. | Regression of fibrosis/cirrhosis by Glycine propionyl-l-carnitine treatment in d-Galactosamine induced chronic liver damage | |
| Dutta et al. | Plant-derived cell-penetrating microprotein α-astratide aM1 targets Akt signaling and alleviates insulin resistance | |
| Yang et al. | Intestinal GSTpi deficiency exacerbates the severity of experimental hyperlipidemic acute pancreatitis | |
| EP4456905B1 (en) | Probiotic bacterial communities for use in the treatment of a liver disease | |
| US20250268855A1 (en) | Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissues | |
| Zhu et al. | Effects of Celastrus orbiculatus on Epithelial Mesenchymal Transition in Gastric Mucosal Epithelial Cells by Inhibiting Lgr 5 Expression from Rats with Gastric Precancerous Lesions | |
| CN115572321B (zh) | 一种酵母肽及其制备方法和应用 | |
| Nur et al. | Antihypertensive Effect of Rice Bran Derived Amino Acids Through Modulation of iNOS Expression and Renal Histopathology in DOCA Salt Induced Hypertensive Rats | |
| Kim et al. | Lean metabolic dysfunction-associated steatotic disease is reversed by betulinic acid, a therapeutic triterpene from birch bark | |
| Kang et al. | The effect of gelatinized brown rice extract on type 2 diabetes mellitus via inhibition of insulin resistance mediators in HepG2 cells | |
| Ye et al. | Salvianolic acid A attenuates Angiotensin II-induced cardiac fibrosis through regulating the Txnip signaling pathway |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20241018 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20241119 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241119 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241119 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241119 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241121 |